Go Back
Go Back

Day 2

34 P. Nikolopoulos - B. MRI response assessment - mrTRG pitfalls, fibrosis vs residual tumor, what imaging tells the surgeon.

34 P. Nikolopoulos - B. MRI response assessment - mrTRG pitf...

35 B. Jansen-Winkeln - C. W&W surveillance - imaging and endoscopy schedule, ctDNA role, regrowth detection and salvage TME.

35 B. Jansen-Winkeln - C. W&W surveillance - imaging and end...

36 B. Brenner - Immunotherapy for localized rectal cancer.

36 B. Brenner - Immunotherapy for localized rectal cancer.

37 N. Karangeli - Case: dMMR rectal cancer: neoadjuvant IO and surgery avoidance

37 N. Karangeli - Case: dMMR rectal cancer: neoadjuvant IO a...

38 M. Frountzas - A. Patient selection for surgery avoidance - Cercek NEJM data, 3-year follow-up, eligibility criteria.

38 M. Frountzas - A. Patient selection for surgery avoidance...

39 Ch. Kontovounisios - B. Salvage TME after local regrowth - timing, surgical planes after IO, what patients must be told upfront.

39 Ch. Kontovounisios - B. Salvage TME after local regrowth...

40 P. Nikolopoulos - C. MRI after IO - how response patterns differ from post-CRT and what constitutes true CR.

40 P. Nikolopoulos - C. MRI after IO - how response patterns...

41 Th. Tegos - D. Catastrophic irAEs that alter the plan - grade 3-4 toxicity, IO discontinuation, bridging to surgery.

41 Th. Tegos - D. Catastrophic irAEs that alter the plan - g...

42 D. Ziogas - Targeting Claudin 18.2 in upper & lower GI malignancies.

42 D. Ziogas - Targeting Claudin 18.2 in upper & lower GI ma...

43 N. Boltsis - Case: High-risk low T1 rectal cancer after ESD: TME or organ preservation?

43 N. Boltsis - Case: High-risk low T1 rectal cancer after E...

44 D. Paradellis - A. Completion TME - oncologic rationale, APR vs intersphincteric approach, counselling this patient.

44 D. Paradellis - A. Completion TME - oncologic rationale,...

45 K. Barbati - B. LN metastasis risk in SM3 T1 - histologic features that drive the decision; what the path report must include.

45 K. Barbati - B. LN metastasis risk in SM3 T1 - histologic...

46 Th. Thomaidis - C. Endoscopic resection in the low rectum - ESD vs TAMIS, specimen quality, when re-excision is feasible.

46 Th. Thomaidis - C. Endoscopic resection in the low rectum...

47 E. Mosa - D. Adjuvant CRT as organ preservation in high-risk T1 - evidence base, dose, technique, expectations.

47 E. Mosa - D. Adjuvant CRT as organ preservation in high-r...

48 M. Moehler - Novelties around the corner.

48 M. Moehler - Novelties around the corner.